Preparation and in-vitro evaluation of fluorometholone cubosomes for ocular delivery

Document Type : Research Paper

Authors

1 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

4 Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Abstract

Objective(s): In this study, ocular drug delivery systems with a dispersed lipid liquid crystal (cubosomes) containing fluorometholone were used for sustained release and increased permeability to the eye.
Materials and Methods: To obtain the best Cubosomes, 6 formulations (F) were prepared. To prepare the F1, glycerol monooleate (GMO) and water containing fluorometholone were vortexed.  After one week, when the liquid crystal gel formed, 0.5 g of the liquid crystal gel was added to 9.5 g of a 1% (w/w%) aqueous solution of Polaxamer F-127, and the mixture were homogenized and sonicated.
Results: The data showed that increasing the weight of gel from 0.5 g to 1.0 g (F2) did not result in a significant increase in drug loading, indicating that increasing the GMO concentration did not affect drug loading. The addition of cyclodextrin to the formulation (F3), along with an increase in cyclodextrin concentration from a molar ratio of 5:1 to 10:1 (F4), did not create a significant alternation in drug loading. Furthermore, the addition of phosphatidyl choline (PC) to the GMO (F5) did not cause a significant change in drug loading. Finally, in formulation F6 ( in which GMO, Polaxamer, and the drug was dissolved in ethanol, the ethanol was removed, and the mixture was dispersed in water) the resulting cubosomes showed a higher drug loading efficiency compared to other formulations. Accelerated stability studies of optimal formulation (F6) according to the ICH Q1A(R2) guideline demonstrated no significant changes in physical characterization and in-vitro release evaluation, indicating complete formulation stability.
Conclusion: Cubosomes can be used as suitable carriers for fluorometholone delivery to eye.

Keywords

References

1.    Rani T, Mohit S. An insight to ophthalmic in situ gel: an overview. Int Res J Pharm 2012;3(3):16-21.
2.    Malaekeh-Nikouei B, Sajadi Tabassi SA, Ashari H, Gholamzadeh A. Evaluation the effect of cyclodextrin complexation on aqueous solubility of fluorometholone to achieve ophthalmic solution. J Incl Phenom Macrocycl Chem 2009;65:335-340.
3.    Noh G, Keum T, Seo J-E, Choi J, Rakesh B, Shrawani L, et al. Development and evaluation of a water soluble fluorometholone eye drop formulation employing polymeric micelle. Pharmaceutics. 2018;10(4):208-223.
4.    Baba K, Hashida N, Tujikawa M, Quantock AJ, Nishida K. The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes. Int J Pharm 2021;592:120067.
5.    El-Gendy MA, Mansour M, El-Assal MI, Ishak RA, Mortada ND. Delineating penetration enhancer-enriched liquid crystalline nanostructures as novel platforms for improved ophthalmic delivery. Int J Pharm 2020;582:119313.
6.    Bessone CDV, Akhlaghi SP, Tártara LI, Quinteros DA, Loh W, Allemandi DA. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma. Eur J Pharm Sci 2021;160:105748.
7.    Zarei-Ghanavati S, Malaekeh-Nikouei B, Pourmazar R, Seyedi S. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration. J Ocul Pharmacol Ther 2012;28(5):502-506.
8.    Huang J, Peng T, Li Y, Zhan Z, Zeng Y, Huang Y, et al. Ocular cubosome drug delivery system for timolol maleate: preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS Pharmscitech. 2017;18:2919-2926.
9.    Ali Z, Sharma PK, Warsi MH. Fabrication and evaluation of ketorolac loaded cubosome for ocular drug delivery. J Appl Pharm Sci 2016;6(9):204-208.
10.    Sanjana A, Ahmed MG, BH JG. Development and evaluation of dexamethasone loaded cubosomes for the treatment of vitiligo. Mater Today: Proc 2022;50:197-205.
11.    Han S, Shen J-q, Gan Y, Geng H-m, Zhang X-x, Zhu C-l, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin 2010;31(8):990-998.
12.    Milak S, Chemelli A, Glatter O, Zimmer A. Vancomycin ocular delivery systems based on glycerol monooleate reversed hexagonal and reversed cubic liquid crystalline phases. Eur J Pharm Biopharm 2019;139:279-290.
13.    Younes NF, Abdel-Halim SA, Elassasy AI. Corneal targeted Sertaconazole nitrate loaded cubosomes: preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies. Int J Pharm 2018;553(1-2):386-397.
14.    Usach I, Martinez R, Festini T, Peris J-E. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 2019;36:2986-2996.
15.    Miao Y, Jia B, Chen M, Zhang W. Preparation and characterization of solid lipid microparticles with liquid crystal structure. Mol Cryst Liq 2016;633(1):110-122.
16.    Hundekar YR, Saboji J, Patil S, Nanjwade B. Preparation and evaluation of diclofenac sodium cubosomes for percutaneous administration. World J Pharm Pharm Sci 2014;3(1):523-539.
17.    Barauskas J, Johnsson M, Joabsson F, Tiberg F. Cubic phase nanoparticles (cubosome): principles for controlling size, structure, and stability. Langmuir 2005;21(6):2569-2577.
18.    Xingqi W, Yong Z, Xing L, Yang W, Jie H, Rongfeng H, et al. Cubic and hexagonal liquid crystal gels for ocular delivery with enhanced effect of pilocarpine nitrate on anti-glaucoma treatment. Drug Deliv 2019;26(1):952-964.
19.    Alharbi WS, Hosny KM. Development and optimization of ocular in situ gels loaded with ciprofloxacin cubic liquid crystalline nanoparticles. J Drug Deliv Sci Technol 2020;57:101710.
Nanomedicine Journal
Volume 10, Issue 4
October 2023
Pages 304-312

Files

Share

How to cite

Statistics